

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Foster Aaron E.</u>  (Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800  (Street) HOUSTON TX 77030  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/11/2019	3. Issuer Name and Ticker or Trading Symbol (Check all applicable) <b>BELLICUM PHARMACEUTICALS, INC [ BLCM ]</b>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Sr VP, Head of Research	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,737	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	10/27/2024	Common Stock	23,529	7.47	D	
Stock Option (right to buy)	(2)	02/23/2025	Common Stock	8,000	23.47	D	
Stock Option (right to buy)	(3)	01/03/2026	Common Stock	15,000	19	D	
Stock Option (right to buy)	(4)	05/31/2026	Common Stock	30,000	12.39	D	
Stock Option (right to buy)	(5)	01/02/2027	Common Stock	4,500	13.89	D	
Stock Option (right to buy)	(6)	07/02/2027	Common Stock	10,500	11.7	D	
Stock Option (right to buy)	(7)	01/01/2028	Common Stock	18,000	9.23	D	
Stock Option (right to buy)	(8)	07/01/2028	Common Stock	42,000	7.72	D	
Stock Option (right to buy)	(9)	01/31/2029	Common Stock	50,000	3.35	D	
Restricted Stock Units	(10)	(10)	Common Stock	1,250	(11)	D	
Restricted Stock Units	(12)	(12)	Common Stock	7,500	(11)	D	

Explanation of Responses:

- 25% of the shares subject to the stock option vest and become exercisable on October 28, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on February 24, 2016, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on January 4, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on June 1, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on July 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on July 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- On January 3, 2017, the reporting person was granted restricted stock units (the "RSUs") for 2,500 shares. The RSUs vest in four annual installments beginning on January 3, 2018.
- Each RSU represents a contingent right to receive one share of the Issuer common stock.
- On January 2, 2018, the reporting person was granted the RSUs for 10,000 shares. The RSUs vest in four equal annual installments beginning on January 2, 2019.

Remarks:

EXHIBIT LIST: EX-24 power of attorney

/s/ Rosemary Y. Williams, Attorney-in-Fact      02/20/2019  
 \*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all, by these presents, that the undersigned hereby constitutes and appoints each of Richard A. Fair, Rosemary Y. Williams and Shane M. Ward, signing in  
(1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of Bellicum Pharmaceuticals  
(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete  
(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the future  
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, proper and  
This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with the  
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of February, 2019.

/s/ Aaron E. Foster  
(Signature)  
Aaron E. Foster  
(Print Name)